A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Sarcopenia

In brief

This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.

Key facts

Study ID
NCT02468674
Run by
Novartis Pharmaceuticals
People needed
160
Starts
2015-07-22
Expected to finish
2018-12-03
Last updated by the study team
2020-06-16

Who can join

Age: 70 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.